



<DATE>

<NAME>

<ADDRESS>

<CSZ>

Dear University of Arkansas Member,

In an effort to provide appropriate, affordable health care options while managing drug costs, the University of Arkansas prescription drug plan will move Savaysa and Pradaxa to our list of non-covered drugs effective October 1, 2018. As a result, you will see your cost share increase. We suggest you speak with your physician about lower-cost alternatives and the therapy most appropriate for your care. Alternatives include Eliquis (apixaban) and Xarelto (rivaroxaban) tablets.

The above change to your prescription drug plan is directed by the University of Arkansas Pharmacy Advisory Committee, who strive to maintain affordable and appropriate healthcare benefits.

If you have questions, please contact MedImpact Healthcare Systems, Inc. at 1-800-788-2949.

Sincerely,

MedImpact and the University of Arkansas Pharmacy Advisory Committee

***The University of Arkansas' prescription drug formulary, administered by MedImpact, is maintained by the University of Arkansas System's Pharmacy Advisory Committee. The Pharmacy Advisory Committee is composed of U of A administrators, AON Hewitt Consultants, Med Impact-PBM vendors, and both faculty and clinical pharmacists, who advise the Committee on the most recent medical research results. The recommendations by the committee are based on the latest available evidence-based studies.***